Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.75 | N/A | +4.30% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.75 | N/A | +4.30% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains positive about the company's strategic direction. They emphasized ongoing investments in innovation and customer engagement.
Management highlighted the strong performance in key product lines.
They expressed confidence in long-term growth despite current market challenges.
Zoetis reported a better-than-expected EPS, indicating solid performance in profitability. However, the stock fell 4.2% in reaction, likely due to a lack of revenue details and no updated guidance. Investors may be cautious given the absence of forward-looking statements.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Apr 30, 2018